image: Leadership from Insilico Medicine (“Insilico”, HKEX:03696), a world-leading artificial intelligence (AI)-driven drug discovery company, will attend the 44th Annual J.P. Morgan Healthcare Conference Jan. 12-15, 2026, in San Francisco
Credit: Insilico Medicine
Leadership from Insilico Medicine (“Insilico”, HKEX:03696), a world-leading artificial intelligence (AI)-driven drug discovery company, will attend the 44th Annual J.P. Morgan Healthcare Conference Jan. 12-15, 2026, in San Francisco.
Representatives from Insilico Medicine including founder, CEO & CBO Alex Zhavoronkov, PhD will be available throughout the week for one-on-one meetings with investors, media, and potential partners. Additionally, Insilico representatives will be hosting a station at the JPM Detox Breakfast 2026: Pharma & MedTech Event, Wednesday, January 14 (8:00 - 10:30 AM PST), located at the Capgemini Applied Innovation Exchange (AIE). Visit the station during the event to explore Insilico’s groundbreaking collaboration with Capgemini and experience live demos showcasing Pharmaceutical Superintelligence in action.
Generative AI and automation are transforming how medicines are discovered and developed, and Insilico is helping lead this shift through its end-to-end Pharma.AI platform. Insilico’s diversified pipeline includes 40+ programs discovered using Pharma.AI, with 27 developmental candidates nominated since 2021 and 10+ programs that have received IND approval. Key clinical-stage programs include Rentosertib (ISM001-055), an AI-discovered and AI-designed TNIK inhibitor for idiopathic pulmonary fibrosis (IPF) that has reported positive topline results from a Phase IIa trial, as well as multiple programs progressing through Phase I clinical development.
Beyond clinical programs, Insilico is advancing a growing portfolio across immunology, inflammation, and cardiometabolic disease. In neuroinflammation/CNS, Insilico has recently reported IND-enabling completion for ISM8969, an oral, brain-penetrant NLRP3 inhibitor. Insilico continues to expand its partnering footprint across both platform and pipeline collaborations. Most recently, Insilico announced a multi-year oncology R&D collaboration with Servier valued at up to US$888 million, underscoring growing industry adoption of AI-enabled discovery and development approaches.
Insilico has achieved AI-driven drug discovery collaborations with other companies including Fosun Pharma, Sanofi, and Eli Lilly, and has delivered R&D milestones across multiple collaborations. By integrating advanced AI and automation technologies, Insilico has significantly improved the efficiency of early-stage drug development in real-world practices, setting a benchmark for AI-driven drug discovery. Whereas traditional early-stage drug discovery typically requires 2.5 to 4 years, more than 20+ of Insilico’s internal programs initiated between 2021 and 2024 achieved PCC nomination in just 12 to 18 months on average, with only about 60–200 molecules synthesized and tested per program.
About Insilico Medicine (03696.HK)
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com
To request a meeting, please contact bd@insilicomedicine.com (business development), media@insilicomedicine.com (media), or ir@insilico.ai (investors).